Meiji and Symphogen call time on infection research alliance
This article was originally published in Scrip
Executive Summary
Meiji Seika Pharma and the Danish antibody venture Symphogen have agreed to end an anti-infective R&D collaboration stretching back to 2006, with the Japanese firm pointing to "changes in the market environment in the expected indications" as the main reason.